Several brokerages have updated their recommendations and price targets on shares of Boston Scientific Corporation (NYSE: BSX) in the last few weeks:

  • 8/9/2017 – Boston Scientific Corporation had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 8/1/2017 – Boston Scientific Corporation was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/1/2017 – Boston Scientific Corporation had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $31.00 price target on the stock, up previously from $30.00.
  • 7/31/2017 – Boston Scientific Corporation was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Boston Scientific posted a better-than-expected second quarter, with earnings and revenues both remaining ahead of the Zacks Consensus Estimate. On a positive note, the company is leaving no stone unturned to strengthen its core businesses and invest more in global markets. Among the recent developments, worth mentioning is the company’s acquisition of Symetis, in a bid to fortify its structural heart business in Europe. We are also encouraged with the company gaining a number of product approvals both in the domestic and overseas markets. Notably, the company received an FDA approval for the RESONATE family of ICD and CRT-D systems. Yet, the recent recall of its Lotus range of heart devices hampered sales in the quarter. Also the unimpressive defibrillator performance within the core CRM continues to remain a drag. We are still concerned about the foreign exchange headwind. In general, over the past three months, Boston Scientific is trading below the broader industry.”
  • 7/30/2017 – Boston Scientific Corporation had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $32.00 price target on the stock.
  • 7/28/2017 – Boston Scientific Corporation had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $32.00 price target on the stock, up previously from $31.00.
  • 7/28/2017 – Boston Scientific Corporation was given a new $29.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “hold” rating on the stock.
  • 7/25/2017 – Boston Scientific Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/17/2017 – Boston Scientific Corporation had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $31.00 price target on the stock.
  • 7/12/2017 – Boston Scientific Corporation had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $31.00 price target on the stock.
  • 7/11/2017 – Boston Scientific Corporation was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Over the past one month, Boston Scientific was trading below the Zacks categorized broader Medical Products industry. Adverse foreign exchange continues to pose challenges for Boston Scientific. We are concerned with the company’s recall of one of its prime products, Lotus range of heart devices. Also dull defibrillator sale within core CRM continues to remain a drag for the overall growth. The woes of challenging economy and competitive landscape continue to weigh the stock. However, on the positive side, the company is leaving no stone unturned to strengthen its core businesses and invest in innovations and global markets. The company recently received CE mark for its Vercise Gevia DBS System which is expected to boost its European business. The increased top line guidance for 2017 also buoys optimism.”
  • 7/6/2017 – Boston Scientific Corporation was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 6/29/2017 – Boston Scientific Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “For the last three months, Boston Scientific has been trading above the broader Medical products industry. The company is leaving no stone unturned to strengthen its core businesses and invest in innovations and global markets. The company recently received CE mark for its Vercise Gevia DBS System which is expected to boost its European business. Managment also presented favorable clinical BT study which is encouraging. The increased top line guidance for 2017 also buoys optimism. On the flip side, while adverse foreign exchange continues to pose challenges, we are concerned with the company’s recall of one of its prime products, Lotus range of heart devices. Also dull defibrillator sale within core CRM continues to remain a drag for the overall growth. The woes of challenging economy and competitive landscape continue to weigh the stock.”
  • 6/28/2017 – Boston Scientific Corporation had its price target raised by analysts at Barclays PLC from $30.00 to $31.00. They now have an “overweight” rating on the stock.
  • 6/28/2017 – Boston Scientific Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $31.00 price target on the stock. According to Zacks, “Boston Scientific posted a mixed first quarter, with earnings missing the Zacks Consensus Estimate and revenues ahead of the mark. While adverse foreign exchange continue to pose challenges, we are concerned with the company’s recent recall of one of its prime products, Lotus range of heart devices. Also dull defibrillator sale within core CRM continues to remain a drag for the overall growth. Accordingly, the share price trend, which remained below the broader industry over majority of the past three months on challenging economy, competitive landscape and currency headwinds, has continued to remain the same post the first quarter earnings release. Nevertheless, Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in innovations and global markets, which accounted for higher sales across all its geographies in the first quarter. The increased top line guidance for 2017 also buoys optimism.”
  • 6/28/2017 – Boston Scientific Corporation had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 6/28/2017 – Boston Scientific Corporation had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $28.00 price target on the stock.
  • 6/28/2017 – Boston Scientific Corporation had its price target raised by analysts at Stifel Nicolaus from $30.00 to $32.00. They now have a “hold” rating on the stock.
  • 6/28/2017 – Boston Scientific Corporation had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $31.00 price target on the stock, up previously from $27.00.
  • 6/22/2017 – Boston Scientific Corporation had its price target raised by analysts at Needham & Company LLC from $30.00 to $32.00. They now have a “buy” rating on the stock.
  • 6/21/2017 – Boston Scientific Corporation had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $30.00 price target on the stock.
  • 6/16/2017 – Boston Scientific Corporation had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $31.00 price target on the stock, up previously from $29.50.

Shares of Boston Scientific Corporation (NYSE BSX) opened at 26.26 on Friday. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51. The company has a market cap of $36.03 billion, a P/E ratio of 46.98 and a beta of 1.09. The firm has a 50-day moving average price of $27.38 and a 200 day moving average price of $26.02.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.01. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.27 EPS. Equities analysts predict that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

In other news, SVP John Bradley Sorenson sold 7,900 shares of Boston Scientific Corporation stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $26.37, for a total value of $208,323.00. Following the completion of the transaction, the senior vice president now owns 21,680 shares in the company, valued at approximately $571,701.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kevin J. Ballinger sold 28,864 shares of Boston Scientific Corporation stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $26.14, for a total value of $754,504.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 236,489 shares of company stock valued at $6,440,888. Company insiders own 0.74% of the company’s stock.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.